MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehac284

Медицинская библиотека · European heart journal · 2022

Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.

Valgimigli Marco, Smits Pieter C, Frigoli Enrico, Bongiovanni Dario, Tijssen Jan, Hovasse Thomas, Mafragi Al, Ruifrok Willem Theodoor, Karageorgiev Dimitar, Aminian Adel, Garducci Stefano, Merkely Bela, Routledge Helen, Ando Kenji, Diaz Fernandez Josè Francisco, Cuisset Thomas, Nesa Malik Fazila Tun, Halabi Majdi, Belle Loic, Din Jehangir, Beygui Farzin, Abhyankar Atul, Reczuch Krzysztof, Pedrazzini Giovanni, Heg Dik, Vranckx Pascal, MASTER DAPT Investigators

Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIM: To assess the effects of 1- or ≥3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS).

METHODS AND

RESULTS

In the MASTER DAPT trial, 3383 patients underwent non-complex (abbreviated DAPT, n = 1707; standard DAPT, n = 1676) and 1196 complex (abbreviated DAPT, n = 588; standard DAPT, n = 608) PCI. Co-primary outcomes at 335 days were net adverse clinical events [NACE; composite of all-cause death, myocardial infarction, stroke, and bleeding academic research consortium (BARC) 3 or 5 bleeding events]; major adverse cardiac or cerebral events (MACCE; all-cause death, myocardial infarction, and stroke); and Types 2, 3, or 5 BARC bleeding. Net adverse clinical events and MACCE did not differ with abbreviated vs. standard DAPT among patients with complex [hazard ratio (HR): 1.03, 95% confidence interval (CI): 0.69-1.52, and HR: 1.24, 95% CI: 0.79-1.92, respectively] and non-complex PCI (HR: 0.90, 95% CI: 0.71-1.15, and HR: 0.91, 95% CI: 0.69-1.21; Pinteraction = 0.60 and 0.26, respectively). BARC 2, 3, or 5 was reduced with abbreviated DAPT in patients with and without complex PCI (HR: 0.64; 95% CI: 0.42-0.98, and HR: 0.70; 95% CI: 0.55-0.89; Pinteraction = 0.72). Among the 2816 patients with complex PCI and/or ACS, NACE and MACCE did not differ and BARC 2, 3, or 5 was lower with abbreviated DAPT.

CONCLUSION

In HBR patients free from recurrent ischaemic events at 1 month, DAPT discontinuation was associated with similar NACE and MACCE and lower bleeding rates compared with standard DAPT, regardless of PCI or patient complexity.

CLINICAL TRIAL REGISTRATION: This trial is registered with ClinicalTrials.gov, number NCT03023020, and is closed to new participants, with follow-up completed.

Для цитирования: Valgimigli Marco, Smits Pieter C, Frigoli Enrico, Bongiovanni Dario, Tijssen Jan, Hovasse Thomas, Mafragi Al, Ruifrok Willem Theodoor, Karageorgiev Dimitar, Aminian Adel, Garducci Stefano, Merkely Bela, Routledge Helen, Ando Kenji, Diaz Fernandez Josè Francisco, Cuisset Thomas, Nesa Malik Fazila Tun, Halabi Majdi, Belle Loic, Din Jehangir, Beygui Farzin, Abhyankar Atul, Reczuch Krzysztof, Pedrazzini Giovanni, Heg Dik, Vranckx Pascal, MASTER DAPT Investigators. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.. European heart journal. 2022. DOI: 10.1093/eurheartj/ehac284.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.